Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change
Authors:
- 1 March 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (5) , 1916-1924
Abstract
Recently, we published the existence of 2 populations of anti-β2-glycoprotein I (β2-GPI) IgG antibodies. Type A antibodies recognize epitope G40-R43 in domain I of β2-GPI and are strongly associated with thrombosis. Type B antibodies recognize other parts of β2-GPI and are not associated with thrombosis. In this study we demonstrate that type A antibodies only recognize plasma-purified β2-GPI when coated onto a negatively charged surface and not when coated onto a neutrally charged surface. The affinity of type B antibodies toward plasma-purified β2-GPI was independent of the charge of the surface to which β2-GPI was coated. Type A antibodies did not recognize plasma-purified β2-GPI in solution, whereas they did recognize recombinant β2-GPI both in solution and coated onto a neutrally charged plate. When the carbohydrate chains were removed from plasma-purified β2-GPI, we found that type A antibodies did recognize the protein in solution. This supports the hypothesis that the difference in recognition of plasma-purified and recombinant β2-GPI is caused by the difference in glycosylation and that epitope G40-R43 of plasma-purified β2-GPI is covered by a carbohydrate chain. Type A anti-β2-GPI antibodies can only recognize this epitope when this carbohydrate chain is displaced as a result of a conformational change. This finding has major implications both for the detection of pathogenic anti-β2-GPI antibodies and the comprehension of the pathophysiology of the antiphospholipid syndrome.Keywords
This publication has 34 references indexed in Scilit:
- Binding of β2–glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cellsBlood, 2005
- β2-Glycoprotein I, the playmaker of the antiphospholipid syndromeClinical Immunology, 2004
- Consensus guidelines on anti-cardiolipin antibody testing and reportingPathology, 2004
- Anti-β2-glycoprotein I autoantibodies require an antigen density threshold, consistent with divalent bindingLupus, 2003
- Solution Structure of Human and Bovine β2-Glycoprotein I Revealed by Small-angle X-ray ScatteringJournal of Molecular Biology, 2002
- Dimers of β2-Glycoprotein I Mimic thein Vitro Effects of β2-Glycoprotein I-Anti-β2-glycoprotein I Antibody ComplexesJournal of Biological Chemistry, 2001
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Role of Divalency in the High-Affinity Binding of Anticardiolipin Antibody−β2-Glycoprotein I Complexes to Lipid MembranesBiochemistry, 1996
- Activity, disulphate mapping and structural modelling of the fifth domain of human β2‐glycoprotein IFEBS Letters, 1992
- Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.Annals of the Rheumatic Diseases, 1988